An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Trikafta

Chemical Nameelexacaftor, ivacaftor, and tezacaftor
Dosage FormTablet (oral; 100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor, co-packaged with 150 mg ivacaftor)
Drug ClassCFTR potentiators
SystemRespiratory
CompanyVertex Pharms Inc
Approval Year2019

Indication

  • Trikafta is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.
Last updated on 6/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Trikafta (elexacaftor, ivacaftor, and tezacaftor) Prescribing Information2020Vertex Pharmaceuticals
Document TitleYearSource
Modulator treatments for cystic fibrosis: effectiveness and value.2020ICER
Document TitleYearSource
Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review.2020Journal of The Academy of Nutrition and Dietetics
From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis. 2020International Journal of Molecular Sciences
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).2020Cochrane Database of Systematic Reviews
Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review.2020Journal of Clinical Medicine